导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.82% | 3449/4773 |
| 近一周 | -0.28% | 181/5462 |
| 近一月 | 3.82% | 112/5421 |
| 近一季 | 2.50% | 463/5209 |
| 近半年 | 0.98% | 1094/4920 |
| 近一年 | -1.75% | 2915/4366 |
| 近两年 | 35.44% | 2082/2954 |
| 近三年 | 36.05% | 833/2253 |
| 成立以来 | 140.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.11% 4350/4961 |
-5.23% 3552/5312 |
- - |
- - |
| 2025 | 13.75% 2629/4813 |
-0.11% 2067/3635 |
10.27% 257/4076 |
-4.47% 4025/4524 |
8.11% 265/4813 |
| 2024 | 37.71% 45/3463 |
4.71% 436/2808 |
3.21% 278/3014 |
24.23% 338/3129 |
2.57% 931/3463 |
| 2023 | -0.69% 465/2656 |
-1.03% 1844/2280 |
2.83% 122/2385 |
5.72% 83/2515 |
-7.70% 2194/2655 |
| 2022 | -9.28% 171/2207 |
-4.72% 171/1919 |
-1.04% 1668/2016 |
-10.36% 389/2113 |
7.34% 318/2208 |
| 2021 | -10.37% 1095/1822 |
-0.60% 376/1255 |
-3.79% 1253/1330 |
-6.26% 911/1466 |
-0.02% 1184/1822 |
| 2020 | 2.25% 921/1250 |
-14.87% 973/1028 |
3.95% 922/1067 |
9.73% 630/1164 |
5.31% 791/1184 |
| 2019 | 33.92% 419/1092 |
26.21% 421/754 |
1.89% 107/804 |
-2.50% 703/850 |
6.80% 545/918 |
| 2018 | -16.99% 122/834 |
- - |
- - |
- - |
-10.02% 171/691 |
| 2017 | 21.89% 159/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.08% 168/605 |
- - |
- - |
- - |
- - |
| 2015 | -8.94% 290/575 |
- - |
- - |
- - |
- - |
| 2014 | 89.04% 3/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.46% 115/186 |
- - |
- - |
- - |
- - |
| 2012 | 21.68% 3/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国泰上证180金融ETF VS. 长安沪深300非周期A(740101) |